Edition:
United States

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

16.63USD
4:00pm EDT
Change (% chg)

$-0.14 (-0.83%)
Prev Close
$16.77
Open
$16.70
Day's High
$16.70
Day's Low
$16.21
Volume
51,937
Avg. Vol
76,470
52-wk High
$30.70
52-wk Low
$13.58

Chart for

About

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform... (more)

Overall

Beta: 1.05
Market Cap(Mil.): $392.35
Shares Outstanding(Mil.): 23.40
Dividend: --
Yield (%): --

Financials

  CNCE.OQ Industry Sector
P/E (TTM): 3.80 213.33 32.89
EPS (TTM): 4.41 -- --
ROI: 68.29 -3.69 13.14
ROE: 72.71 -5.73 15.15

BRIEF-Concert Pharmaceuticals Reports Q1 Loss Per Share $0.19

* CONCERT PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 03 2018

BRIEF-Concert Pharmaceuticals Completes Enrollment In Phase 2A Trial Of CTP-543 In Alopecia Areata

* CONCERT PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 2A TRIAL OF CTP-543 IN ALOPECIA AREATA

Apr 25 2018

BRIEF-Concert Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250.0 Million - SEC Filing

* CONCERT PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250.0 MILLION - SEC FILING Source text (http://bit.ly/2t6Qumw) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 01 2018

BRIEF-Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26

* CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2017 FINANCIAL RESULTS

Mar 01 2018

BRIEF-Concert Pharma Says Intends To Complete Evaluation And Advance CTP-692 Into Clinical Development By 2018 End

* CONCERT PHARMACEUTICALS INC SAYS INTENDS TO COMPLETE PRECLINICAL EVALUATION AND ADVANCE CTP-692 INTO CLINICAL DEVELOPMENT BY YEAR-END 2018 Source text for Eikon: Further company coverage:

Feb 28 2018

BRIEF-Concert Pharmaceuticals Initiates Enrollment In Second Cohort Of CTP-543 Trial

* CONCERT PHARMACEUTICALS ANNOUNCES INITIATION OF ENROLLMENT IN SECOND COHORT OF CTP-543 PHASE 2A TRIAL FOR ALOPECIA AREATA

Feb 12 2018

Earnings vs. Estimates